Vascularized Skin Models
20180072996 · 2018-03-15
Inventors
Cpc classification
C12M21/08
CHEMISTRY; METALLURGY
International classification
Abstract
A synthetic skin tissue is served by at least one synthetic blood vessel and includes a physiologically representative population of cells including fibroblasts and keratinocytes, wherein some keratinocytes are in a differentiated state.
Claims
1. A synthetic skin tissue comprising: a synthetic blood vessel in the form of a hollow tubule comprising a porous polymer and incorporating living endothelial cells and living smooth muscle cells within the vessel; living fibroblasts in a matrix surrounding the vessel; and living keratinocytes disposed atop the fibroblasts, wherein an upper layer of the keratinocytes is in a differentiated state with characteristics of corneocytes.
2. The synthetic tissue of claim 1, wherein said synthetic skin tissue has a thickness of greater than one millimeter.
3. The synthetic tissue of claim 1, wherein said synthetic blood vessel has a branched morphology.
4. The synthetic tissue of claim 1, further comprising living melanocytes disposed among the keratinocytes.
5. The synthetic tissue of claim 1, wherein all of the cells are of human origin.
6. The synthetic tissue of claim 1, disposed inside a perfusion manifold device comprising an inlet port and an outlet port configured to allow fluid flow through said vessel, the device having an opening exposing the the upper layer of keratinocytes to the atmosphere.
7. The synthetic tissue of claim 1, wherein said vessel has a wall comprising one or more concentric layers of the polymer, wherein the vessel has an outer diameter of between 5 and 8000 microns and wherein each individual layer of polymer has a thickness of between 0.1 and 250 microns.
8. A vascularized skin construct comprising: a synthetic skin tissue comprising a synthetic blood vessel in the form of a hollow tubule comprising a porous polymer and incorporating living human endothelial cells and living smooth muscle cells within the vessel, living human fibroblasts in a matrix surrounding the vessel, and living human keratinocytes disposed atop the fibroblasts, wherein an upper layer of the keratinocytes is in a differentiated state with characteristics of corneocytes; and a perfusion manifold device comprising an inlet port and an outlet port configured to allow fluid flow through the vessel, the device having an opening exposing the the upper layer of keratinocytes to the atmosphere.
9. The vascularized skin construct of claim 8, wherein said synthetic skin tissue has a thickness of greater than one millimeter.
10. The vascularized skin construct of claim 8, wherein said synthetic blood vessel has a branched morphology.
11. The synthetic tissue of claim 8, further comprising living human melanocytes disposed among the keratinocytes.
12. The synthetic tissue of claim 8, wherein said vessel has a wall comprising one or more concentric layers of the polymer, wherein the vessel has an outer diameter of between 5 and 8000 microns and wherein each individual layer of polymer has a thickness of between 0.1 and 250 microns.
Description
BRIEF DESCRIPTION OF THE DRAWINGS
[0012]
[0013]
[0014]
[0015]
[0016]
[0017]
DETAILED DESCRIPTION
Definitions
[0018] Before describing the present invention in detail, it is to be understood that the terminology used in the specification is for the purpose of describing particular embodiments, and is not necessarily intended to be limiting. Although many methods, structures and materials similar, modified, or equivalent to those described herein can be used in the practice of the present invention without undue experimentation, the preferred methods, structures and materials are described herein. In describing and claiming the present invention, the following terminology will be used in accordance with the definitions set out below.
[0019] As used herein, the singular forms a, an, and the do not preclude plural referents, unless the content clearly dictates otherwise.
[0020] As used herein, the term and/or includes any and all combinations of one or more of the associated listed items.
[0021] As used herein, the term about when used in conjunction with a stated numerical value or range denotes somewhat more or somewhat less than the stated value or range, to within a range of 10% of that stated.
[0022] Overview
[0023] Previously disclosed in vitro skin models are limited to thin skin, which is generated using the techniques previously described and rely only on passive diffusion of growth media, etc. to maintain those tissues. Providing a functional vasculature, in an in vitro setting, would lead to greatly enhanced capabilities for laboratory investigation. In the absence of an integrative vasculature laboratory skin models cannot accurately represent the conditions of normal skin using current in vitro models.
[0024] Work using organ-on-a-chip devices or other tissue reconstructions have shown in vitro or in vivo tissue cannot be maintained beyond distances greater than 1 mm from the nutrient source (Tian and George 2011; Ehsan and George 2013). This is due to the diffusion limits of growth media and other nutrients. Systems that begin to recapitulate living tissue will need to either effectively model tissue vasculature such that blood vessels can be incorporated into such tissue models, otherwise the models will continue to be limited to thin tissue constructs which have been languishing for decades due to the inability to establish adequate perfusion. This is also true for in vitro skin equivalents, as the skin models generated are limited to 1 mm of thickness due to diffusion limits. However, regions of skin such as the thigh, soles of the feet and palms of the hand typically have skin depths of 3-5 mm. For this reason, tissue transmission studies using skin equivalents are limited to thin skin. The introduction of a perfusable vasculature would permit more complex studies capable of yielding a more complete picture of in vivo conditions, if tissue thickness issues were resolved via perfusion. This would significantly invigorate biomedical research, fortifying the toolkit available to addresses more complex questions allowing investigators to move beyond the limitations of the current state of the art.
[0025] Efforts have been made to incorporate tissue conduits or micro-channels integrated in between live tissue at distances nearing the diffusion limits (Kang, Lee et al. 2016). These conduits can be used to perfuse the living material in order to maintain viability and to generate clinically relevant, size, shape and structural integrity of the tissue being modeled. However, what are overlooked using approaches such as these is that integrated microchannels do not reflect normal vasculature and lack essential cellular components of a blood vessel, mainly endothelial and smooth muscle cells. Blood vessels provide more than simply a conduit for which to transport material. The blood vessel itself is a dynamic system capable of contracting or dilating in response to given cues as well as allowing passive diffusion across the endothelial cell layer for certain molecules, while restricting others (Adams and Alitalo 2007). Further, blood vessels and, more specifically endothelial cells, are capable of considerable response to feedback from tissue. For example, in response to tissue injury or hypoxia, endothelial progenitor cells begin to organize and proliferate, branching off from larger vessels and thus generating a network of smaller vessels to help restore oxygenation and perfusion to the site of injury or hypoxia. This is a basic property of a properly functioning tissue system, yet rigid microchannels do not support angiogenesis and are incapable of responding to such cues limiting the thickness and efficacy of the resultant model.
[0026] As described herein, vascularized human skin can better recapitulate the functional aspects of human skin architecture by providing tissue not only with perfusion but also the dynamic ability to respond to micro-environmental cues and respond accordingly. For example, one embodiment of a vascularized skin construct (VSC) will incorporate synthetic blood vessels to support the growth and maintenance of human skin for long term experimentation. It employs technology recently developed and patented (U.S. Pat. No. 9,157,060) at the U.S. Naval Research Laboratory to construct synthetic blood vessels, termed human endothelial microvessels (HEMV). Typically, a hollow core includes one or more concentric layers which can be populated with various cell types.
[0027] The human endothelial microvessels (HEMV) are constructed using porous, polymeric materials to generate a hollow tubule. In embodiments, the wall thereof includes one or more concentric layers of polymer, wherein the vessel has an outer diameter of between 5 and 8000 microns and wherein each individual layer of polymer has a thickness of between 0.1 and 250 microns. During construction of the tubule, cellular components such as endothelia and/or smooth muscle cells are incorporated therein to generate a cell-laden blood vessel that can recapitulate normal blood vessel function. The HEMV are easily manipulated and placement of the HEMV is unrestricted as the vessels themselves can be incorporated into nearly all dimensions and depths of a tissue model. Furthermore, experiments have established that HEMV respond to environmental cues and are capable of undergoing neovascularization, growing out from the main HEMV and allowing perfusion of the surrounding tissue (
[0028] Use HEMVs for vascularized skin constructs will not only allow thicker skin constructs but also better recapitulate the dynamics of human skin. To construct the VSC, keratinocytes, fibroblasts and melanocytes can be grown in a tissue construct surrounding an embedded HEMV using the device akin to the type disclosed US Patent Application Publication 2016/0130543 (incorporated by reference for this purpose) including a manifold tissue chamber.
[0029] In one embodiment, dermal fibroblasts can make up the dermal layer and act as a connective tissue support for epidermal adhesion. Human dermal fibroblast can be grown in culture, collected and resuspended, for example in in a 5% wt/vol mixture of gelatin methacrylate (GelMA) which serves as the extracellular matrix necessary for fibroblast outgrowth. The mixture of GelMA and dermal fibroblasts can be added to the manifold tissue chamber and photopolymerized to solidify, generating the dermis. Dermal fibroblasts can then be allowed to grow for a period, typically 5-10 days, after which human keratinocytes and human melanocytes (grown in a similar fashion), will can collected and layered on top of the dermis, thus constructing the epidermis. Of note, melanocytes can also be omitted from the model to generate a more basic skin construct. The keratinocyte and melanocyte mixture can be allowed to grow for a period of, for example, 5-10 days after which growth media surrounding the culture will be reduced permitting an air-liquid interface to become established around the skin. The air-liquid interface is an integral step to the protocol which triggers differentiation of the epidermal keratinocytes to generate the differentiated outer layer of the skin, called the stratum corneum. This differentiation has the keratinocytes acquiring characteristics of corneocytes can be observed by morphology and/or changes in protein expression.
[0030] A vascular skin construct was prepared with with an embedded HEMV. During these steps growth media can be recirculated, for example using a peristaltic pump, through HEMVs serving as cellularized conduits to perfuse the VSC, thus maintaining tissue viability and removing waste. Not only do HEMV act as conduits, but they permit normal cellular functions such as engaging in cell signaling between neighboring cells, angiogenesis with generation of branched growths (endothelial sprouts), and response to shear stress during perfusion by appropriately modulating gene expression. One change difference to the original manifold device described in US Patent Application Publication 2016/0130543 involves the use of an alternative to the upper glass plate which is used for purposes of sealing the tissue manifold device. Instead, a partially exposed upper glass plate will allow an air-liquid interface to be established (
[0031] Advantages
[0032] It is possible to have both the VSC and HEMV that have cells only of human origin and eliminate complementarity issues present when using current in vivo models. Not only will this improve the compatibility, but it also provides an alternative to animal models which can be costly, subject to stringent regulation, and may be otherwise undesirable. Ultimately, the functionality of an in vitro VSC improves upon current skin models which lack any type of vasculature and are therefore limited to thin skin modeling. Using the VSC, skin transmission studies, immune-related experimentation, and other more advanced research can be accomplished. Importantly, not only can growth media be perfused through the device in order to maintain tissue survival, but other cell types beyond skin can now become incorporated into the model. For example, blood not only contains plasma proteins but also hematopoietic cells such as human red blood cells and various human-derived white blood cells such as macrophages, B- and T-cells, dendritic cells, etc. which can be incorporated in order to address immune-related activation following a given treatment, studies not possible using current skin equivalents.
[0033] Free-standing engineered blood vessels allow placement into tissue in various positions as desired, unlike other rigid in vitro tissue models with defined parameters.
[0034] Current in vitro skin models are not vascularized. This limits modeling to thin skin (<1 mm). However, many areas of the human body are >3 mm (palms of hands, soles of feet). The disclosed technique allows for better modeling of skin of greater thickness.
[0035] In vivo animal models suffer from reproducibility, species complementarity and access as bans on some studies have been in place since 2013 in the European Union.
[0036] Vascularized skin allows thick skin constructs, skin transmission studies (small molecules, pathogens, chemical agent) transmission across the skin and into the vasculature as well as long-term viability assays.
[0037] This model allows the study of transmission of various agents including compositions intended to be used as topical treatments on the skin, pathogens (including fungi, bacteria, and/or viruses) and the like through the skin. Analysis can be made of distribution to the vasculature by sampling perfused material including blood-simulants passed through the vessel(s) or growth media used in a chamber and testing for transmission/accumulation at various time points.
CONCLUDING REMARKS
[0038] Although the present invention has been described in connection with preferred embodiments thereof, it will be appreciated by those skilled in the art that additions, deletions, modifications, and substitutions not specifically described may be made without departing from the spirit and scope of the invention. Terminology used herein should not be construed as being means-plus-function language unless the term means is expressly used in association therewith.
REFERENCES
[0039] Adams, R. H. and K. Alitalo (2007). Molecular regulation of angiogenesis and lymphangiogenesis. Nat Rev Mol Cell Biol 8(6): 464-478. [0040] Berking, C. and M. Herlyn (2001). Human skin reconstruct models: a new application for studies of melanocyte and melanoma biology. Histol Histopathol 16(2): 669-674. [0041] Conway, K., D. Morgan, et al. (1992). Tumorigenic suppression of a human cutaneous squamous cell carcinoma cell line in the nude mouse skin graft assay. Cancer Res 52(23): 6487-6495. [0042] Ehsan, S. M. and S. C. George (2013). Nonsteady state oxygen transport in engineered tissue: implications for design. Tissue Eng Part A 19(11-12): 1433-1442. [0043] Hartung, T., B. J. Blaauboer, et al. (2011). An expert consortium review of the EC-commissioned report alternative (Non-Animal) methods for cosmetics testing: current status and future prospects2010. ALTEX 28(3): 183-209. [0044] Itoh, M., N. Umegaki-Arao, et al. (2013). Generation of 3D skin equivalents fully reconstituted from human induced pluripotent stem cells (iPSCs). PLoS One 8(10): e77673. [0045] Juhasz, I., S. M. Albelda, et al. (1993). Growth and invasion of human melanomas in human skin grafted to immunodeficient mice. Am J Pathol 143(2): 528-537. [0046] Kang, H. W, S. J. Lee, et al. (2016). A 3D bioprinting system to produce human-scale tissue constructs with structural integrity. Nat Biotechnol 34(3): 312-319. [0047] Natarajan, V. T., P. Ganju, et al. (2014). Multifaceted pathways protect human skin from UV radiation. Nat Chem Biol 10(7): 542-551. [0048] Paolini, C., A. Orecchia, et al. (2013). Skin equivalents: a tool for the discovery and validation of pharmacodynamic biomarkers. Cancer Invest 31(1): 60-66. [0049] Prost-Squarcioni, C. (2006). [Histology of skin and hair follicle]. Med Sci (Paris) 22(2): 131-137. [0050] Roop, D. R., D. R. Lowy, et al. (1986). An activated Harvey ras oncogene produces benign tumours on mouse epidermal tissue. Nature 323(6091): 822-824. [0051] Sonksen, J. a. C., J. (1999). Circulation of the Skin. Current Anaesthesia and Critical Care 10: 58-63. [0052] Sonner, Z., E. Wilder, et al. (2015). The microfluidics of the eccrine sweat gland, including biomarker partitioning, transport, and biosensing implications. Biomicrofluidics 9(3): 031301. [0053] Tian, L. and S. C. George (2011). Biomaterials to prevascularize engineered tissues. J Cardiovasc Transl Res 4(5): 685-698. [0054] von Aulock, S. (2013). EU: final ban on animal experiments for cosmetic ingredients implemented. ALTEX 30(2): 268-269. [0055] Worst, P. K., I. C. Mackenzie, et al. (1982). Reformation of organized epidermal structure by transplantation of suspensions and cultures of epidermal and dermal cells. Cell Tissue Res 225(1): 65-77. [0056] Worst, P. K., E. A. Valentine, et al. (1974). Formation of epidermis after reimplantation of pure primary epidermal cell cultures from perinatal mouse skin. J Natl Cancer Inst 53(4): 1061-1064. [0057] Yamaguchi, Y. and V. J. Hearing (2014). Melanocytes and their diseases. Cold Spring Harb Perspect Med 4(5).